Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00005635
First received: May 2, 2000
Last updated: August 16, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: November 2001 (Final data collection date for primary outcome measure)